Targeting to Prostate Cancer Cells by using Ligand Conjugated Polymeric Nanoparticles as drug carrier

Abstract

Ashique Al Hoque*

Presently wide-ranging research has been carried out to develop nano drug carriers, to overcome the lack of specificity of conventional chemotherapeutic agents for the treatment of prostate cancer, the second most common cancer in men. The aim of the current study is to develop and characterize PLGA nanoparticles (NPs) containing an anticancer agent, tagged with a suitable ligand for targeted delivery of the drug.